An interventional study of Water and Coffee in Excess Intake of Macronutrients, Excess Intake of Micronutrients and Vasopressin Low, sponsored by Region Skane. Completed at 1 site in Sweden. Open to participants aged 20 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-11.
Sponsored by Region Skane · Not applicable, Interventional, and Prevention
39 healthy subjects without medication (except oral contraceptives) aged 20-70 years are recruited via advertisements or through telephone contacts with individuals that had previously participated in population-based cohort studies in Malmö. All subjects are exposed to three different intervention procedures; water and coffee loads (acutely and chronically), or no change from usual fluid intake (as a time-control), respectively in randomized order. The daily intake of coffee or water will amount to 3 L of water and 1 L of coffee, respectively for one week each. The three interventions (water, coffee and control), are separated by three weeks of normal fluid intake as a wash-out period.
By testing if simple life style interventions, i.e., increased water or coffee intake, may affect vasopressin secretion, evaluated as copeptin, we will increase the knowledge as to whether such life style induced changes of copeptin may in turn lead to effects on glucose tolerance as well as on other cardiometabolic risk factors previously shown to be associated with high copeptin level. Thus, the study will lead to further understanding about vasopressin and copeptin release and how life style manipulation of the vasopressin system may influence glucose metabolism and other cardiometabolic risk factors in healthy individuals.
Day 1: The initial examination consists of medical history, clinical examination including office blood pressure, and blood sampling (overnight fasting plasma copeptin (a marker of vasopressin), osmolality, insulin, glucagon, glucose, creatinine, hsCRP and OGTT), and start of 24-h urine collection and 24-h ambulatory blood pressure measurement.
Day 2: After completion of the 24-h urine collection and ABPM, in the fasting state in the morning, office blood pressure will be measured and blood sampling for plasma copeptin, osmolality insulin, glucagon, glucose, creatinine and hsCRP measurement will be performed. Then, during a maximum time period of 20 minutes, subjects will ingest either 1L of water or 4 dL of coffee, or just 10 ml of water (time control). To map the acute coffee or water effect on copeptin, the experiment proceeds with repeated blood sampling every 30 minutes for 4 hours after the first coffee or water intake. Day 1 then continues with the rest of the daily intake, i.e., 2 L of water or 6 dL of coffee in addition to normal food and fluid intakes.
Day 3 to 7: 3 L water per day or 1 L of coffee per day are ingested (or nothing, in the control intervention) in addition to each subject's own food and fluid intake. On days 4 and 6, blood sampling for electrolyte and urea measurement and osmolality will be carried out for reasons of safety and compliance check.
Day 8: Fasting in the morning, office blood pressure, blood sampling (copeptin, osmolality, insulin, glucagon, glucose, creatinine, hsCRP) will be performed and a 24-h urine collection and ABPM will be started.
Day 9: The final examination will consist of clinical examination including office blood pressure and blood sampling (overnight fasting plasma copeptin, osmolality, insulin, glucagon, glucose, creatinine, hsCRP and OGTT), and end of 24-h urine collection and ABPM.
120 studies on the registry are indexed under Diabetes Insipidus; 30 are open to participants now.
This study's enrollment of 39 is below the median of 56 across 67 interventional studies indexed under Diabetes Insipidus.
Browse Diabetes Insipidus studies →Region Skane is the lead sponsor of 382 studies on the registry; 118 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Healthy subjects Age 20-70 years
Exclusion Criteria:
medication (except oral contraceptives) any type of acute illness any type of chronic illness
At intervention day 1, during a maximum time period of 20 minutes, subjects will ingest 1 L of water (still bottled water) to map the acute water effect on the vasopressin marker copeptin (repeated blood sampling every 30 minutes for 4 hours). Day 1 then continues with the rest of the daily intake, i.e., 2 L of extra water (i.e. in addition to each subject's habitual food and fluid intake). Intervention day 2-7: 3 L extra water per day in addition to each subject's habitual food and fluid intake.
Other: Water
At intervention day 1, during a maximum time period of 20 minutes, subjects will ingest 4 dL of coffee to map the acute coffee effect on the vasopressin marker copeptin (repeated blood sampling every 30 minutes for 4 hours). Day 1 then continues with the rest of the daily intake, i.e., 6dL of extra coffee (i.e. in addition to each subject's habitual food and fluid intake). Intervention day 2-7: 1 L extra coffee per day in addition to each subject's habitual food and fluid intake.
Other: Coffee
At intervention day 1, during a maximum time period of 20 minutes, subjects will ingest just 10 ml of water to map the acute effect on the vasopressin marker copeptin (repeated blood sampling every 30 minutes for 4 hours). Day 1 then continues with each subject's habitual food and fluid intake. Intervention day 2-7: Each subject's habitual food and fluid intake.
Other: Control
Please see the associated arm description
Please see the associated arm description
Please see the associated arm description
1 week result on plasma copeptin
Change ("∆-value") between plasma copeptin value (pmol/L) at end of control week and post-intervention values will be calculated. Significance of differences between each intervention and the time-control will be tested using paired t-test or Wilcoxon's paired rank test, depending on normality of distributions.
Time frame: 7 days
1 week result on plasma glucose
Change ("∆-value") between plasma glucose (mmol/L) at end of control week and post-intervention values will be calculated. Significance of differences between each intervention and the time-control will be tested using paired t-test or Wilcoxon's paired rank test, depending on normality of distributions.
Time frame: 7 days
1 week result on plasma insulin
Change ("∆-value") between plasma insulin (IE) at end of control week and post-intervention values will be calculated. Significance of differences between each intervention and the time-control will be tested using paired t-test or Wilcoxon's paired rank test, depending on normality of distributions.
Time frame: 7 days
1 week result on plasma glucagon
Change ("∆-value") between plasma glucagon (pmol/L) at end of control week and post-intervention values will be calculated. Significance of differences between each intervention and the time-control will be tested using paired t-test or Wilcoxon's paired rank test, depending on normality of distributions.
Time frame: 7 days
1 week result on plasma C-reactive protein
Change ("∆-value") between plasma C-reactive protein (mg/L) at end of control week and post-intervention values will be calculated. Significance of differences between each intervention and the time-control will be tested using paired t-test or Wilcoxon's paired rank test, depending on normality of distributions.
Time frame: 7 days
1 week result on plasma creatinine
Change ("∆-value") between plasma creatinine (umol/L) at end of control week and post-intervention values will be calculated. Significance of differences between each intervention and the time-control will be tested using paired t-test or Wilcoxon's paired rank test, depending on normality of distributions.
Time frame: 7 days
1 week result on plasma osmolality
Change ("∆-value") between plasma osmolality (mosm/kg H2O) at end of control week and post-intervention values will be calculated. Significance of differences between each intervention and the time-control will be tested using paired t-test or Wilcoxon's paired rank test, depending on normality of distributions.
Time frame: 7 days
1 week result on urine osmolality
Change ("∆-value") between urine osmolality (mosm/kg H2O) at end of control week and post-intervention values will be calculated. Significance of differences between each intervention and the time-control will be tested using paired t-test or Wilcoxon's paired rank test, depending on normality of distributions.
Time frame: 7 days
1 week result on blood pressure
Change ("∆-value") between blood pressure (mmHg) at end of control week and post-intervention values will be calculated. Significance of differences between each intervention and the time-control will be tested using paired t-test or Wilcoxon's paired rank test, depending on normality of distributions.
Time frame: 7 days
Acute 4-hour effect of intervention on copeptin
To test the hypothesis that acute coffee or water load affects plasma copeptin levels (pmol/L), we will perform paired t-tests (or Wilcoxon's paired rank test in case of no normal distribution) between individual 0 min values (immediately before acute load) and repeated post load values taken each 30 min during 4 hours.
Time frame: 4 hours
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2011 to primary completion in Jan 2016, 60 months.
Of 22 interventional studies with no phase under Diabetes Insipidus, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 60. This study's 60 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.